TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.

Triple-negative breast cancer (TNBC) represents a subgroup of breast cancers (BC) associated with the most aggressive clinical behavior. No targeted therapy is currently available for the treatment of patients with TNBC. In order to discover potential therapeutic targets, we searched for protein kin...

Full description

Bibliographic Details
Main Authors: Virginie Maire, Céline Baldeyron, Marion Richardson, Bruno Tesson, Anne Vincent-Salomon, Eléonore Gravier, Bérengère Marty-Prouvost, Leanne De Koning, Guillem Rigaill, Aurélie Dumont, David Gentien, Emmanuel Barillot, Sergio Roman-Roman, Stéphane Depil, Francisco Cruzalegui, Alain Pierré, Gordon C Tucker, Thierry Dubois
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23700430/pdf/?tool=EBI